Stifel analyst Rick Wise lowered the firm’s price target on Outset Medical (OM) to $8 from $14 and keeps a Buy rating on the shares. The firm, which argues that the 2026 setup is constructive for large-cap MedTech following 2025 pressures, adjusted targets among its coverage and highlights Boston Scientific (BSX), Edwards Lifesciences (EW), and Solventum (SOLV) as its three top ideas entering the year.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OM:
- Outset Medical price target lowered to $7 from $17 at RBC Capital
- Outset Medical management to meet virtually with BTIG
- Outset Medical’s Earnings Call: Mixed Signals and Future Prospects
- Outset Medical price target lowered to $17 from $22 at RBC Capital
- Outset Medical price target lowered to $15 from $25 at TD Cowen